Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
22
datasets available to search
ShareScore release 0.9.0
Dataset results
22 results for “Drug Central”
Drug Repurposing Central Usage Statistics Matomo
<p>Usage for the Open Science publishing portal Drug Repurposing Central created by ScienceOpen as part of the REPO4EU project. This dataset contains visits over time via Matomo Analytics. Current time frame is 01 September, 2023 to 31 August, 2024.</p>
Drug Repurposing Central Portal Usage and Geolocation Statistics
<p>Record-level usage and geolocation statistics by country and organization for the Drug Repurposing Central portal.</p> <p>Covered time frame is from October 2021 to August 2024.</p>
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involveme
ClinicalTrials.gov study NCT00920647. IPD Sharing: YES. Countries: 2. Publications: 1.
Data for paper: Comparing Measures of Centrality in Bipartite Social Networks: A Study of Drug Seeking for Opioid Analgesics
<p>Data and code for paper: Comparing Measures of Centrality in Bipartite Social Networks: A Study of Drug Seeking for Opioid Analgesics</p>
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
ClinicalTrials.gov study NCT05602818. IPD Sharing: YES. Countries: 1. Publications: 0.
Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring
ClinicalTrials.gov study NCT01326767. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
ClinicalTrials.gov study NCT01179828. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients
ClinicalTrials.gov study NCT03409315. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Effect of Different Antihypertensive Drugs on Central Blood Pressure
ClinicalTrials.gov study NCT05328310. IPD Sharing: NO. Countries: 1. Publications: 0.
Information and Communication Technology (ICT) Based Centralized Clinical Trial Monitoring System for Drug Adherence
ClinicalTrials.gov study NCT03136588. IPD Sharing: NO. Countries: 1. Publications: 9.
Data from: Numerical simulations of targeted delivery of magnetic drug aerosols in the human upper and central respiratory system: a validation study
In the present study, we investigate the concept of the targeted delivery of pharmaceutical drug aerosols in an anatomically realistic geometry of the human upper and central respiratory system. The geometry considered extends from the mouth inlet to the 8th generation of the bronchial bifurcations and is identical to the phantom model used in the experimental studies of [Banko {em et al.} (2015), Exp. Fluids, {bf 56} (117):1-12]. In our computer simulations, we combine the transitional Reynolds-Averaged Navier-Stokes (RANS) and the wall-resolved Large Eddy Simulation (LES) methods for the air phase with the Lagrangian approach for the particulate (aerosol) phase. We validated simulations against recently obtained magnetic resonance velocimetry (MRV) measurements of [Banko {em et al.} (2015), Exp. Fluids, {bf 56} (117):1-12] that provide full a 3D mean velocity field for steady inspiratory conditions. Both approaches produced good agreement with experiments, and the transitional RANS approach is selected for the multi-phase simulations of aerosols transport, because of significantly lower computational costs. The local and total deposition efficiency are calculated for different classes of pharmaceutical particles (in the $0.1mu$m$le d_{rm p} le 10mu$m range) without and with a paramagnetic core (the shell-core particles). For the latter, an external magnetic field is imposed. The source of the imposed magnetic field was placed in the proximity of the first bronchial bifurcation. We demonstrated that both total- and local-depositions of aerosols at targeted locations can be significantly increased by an applied magnetization force. This finding confirms the possible potential for further advancement of the magnetic drug targeting (MDT) technique for more efficient treatments for respiratory diseases.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Objectives: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO). Design: Systematic review and network meta-analysis. Participants: Patients from previously reported randomized controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Methods: Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library, and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining/losing ≥15 letters, best-corrected visual acuity (BCVA), and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous hemorrhage (VH), and retinal tear. The software ADDIS (version 1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation. Results: Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining ≥15 letters, aflibercept and ranibizumab were significantly more effective than sham/placebo at 6 months. Regarding patients losing ≥15 letters at 6 months, ranibizumab showed significant improvement compared to dexamethasone. Aflibercept, bevacizumab, or ranibizumab showed greater improvements in BCVA than sham/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit-risk analysis. Conclusions: Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment.
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem
ClinicalTrials.gov study NCT01817075. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Data from: Numerical simulations of targeted delivery of magnetic drug aerosols in the human upper and central respiratory system: a validation study
Open the record for dataset details and reuse information.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Open the record for dataset details and reuse information.
Glucocorticoid receptor-regulated enhancers play a central role in the gene regulatory networks underlying drug addiction
GEO Series GSE193757. Rattus norvegicus. 36 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other; Non-coding RNA profiling by high throughput sequencing.
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering
ClinicalTrials.gov study NCT04356989. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
ClinicalTrials.gov study NCT01045083. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea
ClinicalTrials.gov study NCT05900336. IPD Sharing: NO. Countries: 1. Publications: 0.
Central Analgesic Drugs for the Treatment of Chronic Pain
ClinicalTrials.gov study NCT02223442. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.